Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (£272m) spanning five years because of Washington's request for confidential biological samples.
This move became public after a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman later explained that the US was demanding access to genetic material for research and commercial gain while was unwilling to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued talks to secure a agreement agreeable to both sides so the nation's critical HIV programme can continue.
Wider Background
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a court blocked a related deal with the US after legal challenges were filed about the safety of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to boost transparency and accountability.
As per statements, Sixteen African countries have to date signed these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Effectively, our nation would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our population if a future health crisis arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures previously set up through the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is designed to ensure that when a country provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how future co-operation might be arranged in a manner that honours the sovereignty and interests of both nations."
Medical Community Response
Medical experts expressed it recognised the official position, but suggested that talks need to persist considering much of the nation's HIV programmes depended on external financing.
"Where technical issues arise, including those relating to information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group said.
This impasse highlights the ongoing debate between accepting much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.